Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica

share with twitter share with LinkedIn share with facebook
08/13/2019 | 07:39am EDT

By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the use of Imbruvica in two additional indications.

Janssen said Imbruvica is now approved in combination with obinutuzumab in adults with previously untreated chronic lymphocytic leukemia, and in combination with rituximab for adults with Waldenstrom's macroglobulinemia, a rare and incurable type of non-Hodgkin's lymphoma.

The European Medicines Agency's Committee for Medicinal Products for Human Use in June recommended EC approval of the expanded use of Imbruvica.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
All news about JOHNSON & JOHNSON
09:29aJOHNSON & JOHNSON : - BAND-AID Brand Delivers Modern Day 'CARE Packages' to Fron..
AQ
09:25aJOHNSON & JOHNSON : BAND-AID Brand Delivers Modern Day 'CARE Packages' to Frontl..
AQ
09/21JOHNSON & JOHNSON : BAND-AID® Brand Delivers Modern Day “CARE Packages&rdq..
PU
09/21JOHNSON & JOHNSON : Janssen Presents Findings from Global, Multi-Center Trial Ex..
AQ
09/21JOHNSON & JOHNSON : Janssen Presents Findings from Global, Multi-Center Trial Ex..
PU
09/21Trump suggests Pfizer could win U.S. COVID-19 vaccine approval, JNJ to come l..
RE
09/21Trump suggests Pfizer could win U.S. COVID-19 vaccine approval, JNJ to come l..
RE
09/18Five leading health care companies lost over $65 billion in market cap YTD
AQ
09/17JOHNSON & JOHNSON : NY Files Charges Against J&J Over Opioids -- 2nd Update
DJ
09/17JOHNSON & JOHNSON : NY Files Charges Against J&J Over Opioids -- Update
DJ
More news
Financials (USD)
Sales 2020 80 541 M - -
Net income 2020 16 242 M - -
Net Debt 2020 3 827 M - -
P/E ratio 2020 23,7x
Yield 2020 2,78%
Capitalization 380 B 380 B -
EV / Sales 2020 4,76x
EV / Sales 2021 4,26x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 162,89 $
Last Close Price 144,21 $
Spread / Highest target 24,8%
Spread / Average Target 13,0%
Spread / Lowest Target -2,23%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.14%382 023
ROCHE HOLDING AG7.64%314 692
MERCK & CO., INC.-8.60%210 256
PFIZER, INC.-6.51%200 159
NOVARTIS AG-11.23%196 086
NOVO NORDISK A/S12.49%159 636